CLAIMS

1. Use of ~~A~~a pharmaceutical in the manufacture of a medicament for preventing and/or treating non-ischemic cardiomyopathy, ~~comprising~~wherein the pharmaceutical comprises:

dendritic cells obtained by a method comprising a step of culturing mononuclear cells in the presence of GM-CSF and IL-2 and a step of pulsing the cultured cells with α-galactosylceramide.

2. The use ~~The pharmaceutical~~ according to claim 1, wherein the non-ischemic cardiomyopathy is dilated cardiomyopathy or drug-induced cardiomyopathy caused by an anthracycline-based anticancer agent.

3. The use ~~The pharmaceutical~~ according to claim 1 or 2, further comprising an anthracycline-based anticancer agent.

4. The use ~~The pharmaceutical~~ according to any one of claims 1 to 3, wherein the pharmaceutical is ~~used~~ for use in preventing and/or treating cardiomyopathy of a subject to whom an anthracycline-based anticancer agent has been administered.

~~5. A method of producing a pharmaceutical for preventing and/or treating non-ischemic cardiomyopathy, comprising:~~

~~a step of culturing mononuclear cells in the presence of GM-CSF and IL-2; and~~

~~a step of pulsing the cultured cells with α-galactosylceramide.~~

~~6. The method of producing a pharmaceutical according to claim 5, wherein the non-ischemic cardiomyopathy is dilated cardiomyopathy or drug-induced cardiomyopathy caused by an anthracycline-based~~

~~anticancer agent.~~

~~7~~5. Use of a~~A~~ pharmaceutical in the manufacture of a medicament for inhibiting a decrease in myocardial contractility, wherein the pharmaceutical ~~comprising~~comprises:

dendritic cells obtained by a method comprising a step of culturing mononuclear cells in the presence of GM-CSF and IL-2 and a step of pulsing the cultured cells with α-galactosylceramide.

6~~8~~. Use of ~~A~~a pharmaceutical in the manufacture of a medicament for inhibiting or preventing myocardial cell death, wherein the pharmaceutical ~~comprising~~comprises:

dendritic cells obtained by a method comprising a step of culturing mononuclear cells in the presence of GM-CSF and IL-2 and a step of pulsing the cultured cells with α-galactosylceramide.

~~9~~7. Use of ~~A~~a pharmaceutical in the manufacture of a medicament for inhibiting or improving myocardial atrophy, wherein the pharmaceutical ~~comprising~~comprises:

dendritic cells obtained by a method comprising a step of culturing mononuclear cells in the presence of GM-CSF and IL-2 and a step of pulsing the cultured cells with α-galactosylceramide.

~~10~~8. Use of ~~A~~a pharmaceutical in the manufacture of a medicament for progress-inhibiting and/or treating myocardial fibrosis, wherein the pharmaceutical ~~comprising~~comprises:

dendritic cells obtained by a method comprising a step of culturing mononuclear cells in the presence of GM-CSF and IL-2 and a step of pulsing the cultured cells with α-galactosylceramide.

9. A pharmaceutical for use as a medicament, wherein the

pharmaceutical comprises:

dendritic cells obtained by a method comprising a step of culturing mononuclear cells in the presence of GM-CSF and IL-2 and a step of pulsing the cultured cells with α-galactosylceramide.